Panmure Liberum acts as Nominated Adviser, Joint Bookrunner and Joint Broker on Arecor Therapeutics’ £6.4 million fundraise

We are pleased to announce that Panmure Liberum acted as Nominated Adviser, Joint Bookrunner and Joint Broker on a successful fundraise, raising £6.4m for Arecor Therapeutics plc.

Arecor Limited Cover

Arecor is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products which are safer, more effective and easier-to-use, with a vision to provide improved outcomes and quality of life to patients.

The net proceeds of the fundraise will be used to drive revenue growth across the business, working capital and balance sheet strength with a view to delivering shareholder value. The fundraise will also allow the Company to continue to invest in research and development and drive sales of its Ogluo® product through investment in inventory and in awareness and marketing campaigns in the UK and Germany.

The fundraise comprised a Placing of new shares via an ABB to raise £5.2m, a direct Subscription to raise £1.0m and a Retail Offer via the Winterflood Retail Access Platform (WRAP) to raise £0.16m. 

Panmure Liberum Team

Corporate Advisory – Emma Earl, Freddy Crossley, Mark Rogers, Freddie Wooding, Ivo Macdonald

Corporate Broking – Rupert Dearden, Rauf Munir

Research – Julie Simmonds

Sales – David Cox, Oliver Baxendale, Oliver Houghton, Graham Smith

CIR – Jodi Hutchins

Legal – Noth Malaba

Company Image

London

Ropemaker Place, Level 12 25 Ropemaker Street London EC2Y 9LY [email protected] +44 (0)20 3100 2000

Leeds

Northspring, 36 Park Row Leeds, LS1 5JL [email protected] +44 (0)113 841 9700

Cambridge

50-60 Station Road Cambridge, CB1 2JH [email protected] +44 (0)113 841 9700
Company Image

New York

20th Floor 575 Fifth Avenue New York NY 10017 [email protected] +1 212 596 4800